NVAX Stock – UPDATE 1-Takeda says first patient given Novavax COVID-19 vaccine in Japan clinical trial
(Adds details from second paragraph.)
TOKYO, Feb 24 (Reuters) – Takeda Pharmaceutical Cosaid on Wednesday the first patient had been given Novavax Inc’sCOVID-19 vaccine candidate in a Japanese clinicaltrial.
Takeda, Japan’s biggest drugmaker, is helping bring twoWestern-developed COVID-19 vaccines to the domestic market. Itplans to produce about 250 million doses of the Novavax vaccinein Japan and will import 50 million of the one made by ModernaInc.
The first volunteer was given a Novavax dose as part of acombined phase I and II study of 200 adult volunteers in Japan,Takeda said in a release. A separate domestic study of theModerna vaccine has reached full enrollment after it began lastmonth, the company said.
Pending regulatory approval, Takeda plans to startdistributing the Moderna vaccine in the first half of this year,while Novavax’s is expected in late 2021.
Japan has secured rights to at least 564 million doses ofCOVID-19 vaccines from several overseas makers, the biggestquantity in Asia and more than enough for its population of 126million.
Prime Minister Yoshihide Suga has pledged to have enoughvaccine doses for the population by June before the Summer Gamesin Tokyo, scheduled to start on July 23.(Reporting by Rocky Swift; Editing by Himani Sarkar and GerryDoyle)